<div id="readability-page-1"><p>BayBridge Capital Group LLC acquired a new position in shares of  Johnson &amp; Johnson (NYSE:JNJ - Free Report) in the 3rd quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The fund acquired 6,203 shares of the company's stock, valued at approximately $1,150,000.</p><div><p><span></span><span>Get <strong>Johnson &amp; Johnson</strong> alerts:</span></p></div><ul><li>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li></ul><p>Several other hedge funds have also recently made changes to their positions in JNJ. Clark Asset Management LLC raised its stake in shares of  Johnson &amp; Johnson by 51.6% during the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company's stock worth $1,357,000 after buying an additional 3,025 shares during the period.  Treasurer of the State of North Carolina increased its holdings in  Johnson &amp; Johnson by 8.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company's stock worth $188,638,000 after acquiring an additional 94,957 shares in the last quarter.  Avanza Fonder AB raised its position in  Johnson &amp; Johnson by 2.9% during the second quarter. Avanza Fonder AB now owns 234,647 shares of the company's stock worth $35,842,000 after acquiring an additional 6,566 shares during the period.  Talbot Financial LLC lifted its holdings in  Johnson &amp; Johnson by 4.6% during the third quarter. Talbot Financial LLC now owns 138,424 shares of the company's stock valued at $25,667,000 after purchasing an additional 6,143 shares in the last quarter.  Finally, Winnow Wealth LLC acquired a new stake in shares of  Johnson &amp; Johnson in the second quarter valued at about $295,000. 69.55% of the stock is owned by institutional investors and hedge funds. </p><h2>Analyst Ratings Changes</h2><p>Several research firms have recently commented on JNJ. Morgan Stanley lifted their price target on Johnson &amp; Johnson from $190.00 to $197.00 and gave the stock an &#34;equal weight&#34; rating in a report on Friday, December 12th. Barclays increased their price target on shares of Johnson &amp; Johnson from $176.00 to $197.00 and gave the company an &#34;equal weight&#34; rating in a research note on Tuesday, December 2nd. Wells Fargo &amp; Company upped their price objective on Johnson &amp; Johnson from $212.00 to $230.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, December 12th. Citigroup increased their price objective on Johnson &amp; Johnson from $215.00 to $232.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, December 11th. Finally, BMO Capital Markets  restated an &#34;outperform&#34; rating on shares of Johnson &amp; Johnson in a research report on Thursday, December 11th. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned  a Buy rating and nine have assigned  a Hold rating to the company. Based on data from MarketBeat, the company  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $210.25.</p><ul><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li></ul><p><b>View Our Latest Research Report on JNJ</b></p><h2>Johnson &amp; Johnson Price Performance</h2><p>Shares of NYSE:JNJ opened at $208.01 on Friday. The business has a fifty day simple moving average of $199.39 and a 200-day simple moving average of $180.50. Johnson &amp; Johnson has a 52 week low of $140.68 and a 52 week high of $215.18. The company has a market cap of $501.14 billion, a P/E ratio of 20.08, a P/E/G ratio of 2.25 and a beta of 0.36. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. </p><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson &amp; Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter.  Equities research analysts forecast that  Johnson &amp; Johnson will post 10.58 EPS for the current year. </p><h2>Johnson &amp; Johnson Dividend Announcement</h2><p>The business also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were given a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. Johnson &amp; Johnson's dividend payout ratio  is presently 50.19%. </p><h2>About Johnson &amp; Johnson</h2> (Free Report)<p>Johnson &amp; Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.  </p><p>The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.</p><h2>See Also</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li><li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li><li>Washington prepares for war</li><li>Strange Crystal Metal Outperforms Silicon Up to 100X</li><li>33,000% boom from weird new “AI Fuel?”</li></ul><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>BayBridge Capital Group LLC acquired 6,203 shares of Johnson & Johnson, valued at $1,150,000, in the 3rd quarter. Several hedge funds adjusted their positions in JNJ. Analysts have given JNJ a consensus rating of "Moderate Buy" with an average target price of $210.25. Johnson & Johnson's stock opened at $208.01, with a market cap of $501.14 billion. The company announced a quarterly dividend of $1.30, yielding 2.5%.</p>

BayBridge Capital Group LLC Purchases Shares of 6,203 Johnson & Johnson $JNJ